ASCO

A Clinical Study Finds Pfizer's Dacomitinib Delays The Growth of Lung Cancer Cells Better Than AstraZeneca's Iressa

Medicine & Technology Jun 06, 2017

In the last day of ASCO 2017 annual meeting on Tuesday, researchers presented the data of Dacomitinib that delayed the growth of the lung cancer longer than Gefitinib, trademarked as Iressa in newly diagnosed patients.

Johnson & Johnson's Zytiga Helps Increase Survival Rate For Patient With Severe Prostate Cancer

Jun 05, 2017

American Society of Clinical Oncology (ASCO) presented the research of the effectiveness of Zytiga to boost the survival rate for severe prostate cancers.

ASCO

A Clinical Study Finds Pfizer's Dacomitinib Delays The Growth of Lung Cancer Cells Better Than AstraZeneca's Iressa

Johnson & Johnson's Zytiga Helps Increase Survival Rate For Patient With Severe Prostate Cancer

Most Popular

How Technology Is Changing the Real Estate Industry?

How a Plant-Based Diet Can Protect Against Breast Cancer: Insights from Nutrition Research

Study Reveals High Turnover in Scientific Research Careers: What This Means for Future Scientists

Why It's So Difficult to Lose Weight: The Biological Explanation Behind Obesity

Nikolay Karpenko Biography, Photo, Career, Accomplishments

Recommended Stories

NASA Shuts Down Voyager 2 Science Instrument After 47 Years to Conserve Energy

OpenAI’s Whisper Faces Scrutiny Over Accuracy, Experts Find 'Hallucinated' Text in Transcripts

Martian Ice May Support Microbial Life Beneath Its Surface, New Study Suggests

NASA Astronaut Hospitalized After Returning from Extended Space Mission